Executive Team

Nima FarzanChief Executive Officer & President

Mr. Farzan joined PaxVax in September of 2011 and is currently Chief Executive Officer and President. Nima joined PaxVax from Novartis AG where he spent over seven years in a number of positions of increasing responsibility including pharmaceutical marketing, sales and development in both global and US positions. Most recently, he had been the Vice President of Marketing for Novartis Vaccines USA...

Read more
Mark MeltzExecutive Vice President & Chief Legal Officer

Mr. Meltz joined PaxVax in 2014 as Executive Vice President and Chief Legal Officer and is licensed to practice law in the Commonwealth of Massachusetts.  Prior to joining PaxVax, Mr. Meltz worked at Biogen Idec as the lead lawyer for the U.S. Commercial team that launched Tecfidera, an oral MS blockbuster drug, and for the U.S. Commercial team for Tysabri, an injectable MS drug with a black box...

Read more
Philip MoodyExecutive Vice President & Chief Financial Officer

Mr. Moody joined PaxVax in 2016 as Executive Vice President and Chief Financial Officer. Prior to joining PaxVax, Mr. Moody served as Chief Financial Officer for the North American sector at BTG PLC. In this role, he served as an advisor to the Head of North America at BTG, a company valued at $5 billion, and was responsible for management and oversight of all financial functions for the British-...

Read more
Jonathan F. Smith
Jonathan F. SmithExecutive Vice President & Chief Scientific Officer

Dr. Smith is a pioneer in the development of novel vaccines and vaccine vector systems derived from RNA viruses with more than 25 years of experience in virology, infectious diseases, immunology, and vaccine development. He joined PaxVax from Liquidia, where he was the company’s Chief Scientific Officer, responsible for overseeing research and development programs applying the company’s novel...

Read more
Marc Gurwith, M.D., J.D.
Marc GurwithChief Medical Officer

Dr. Gurwith has served as Chief Medical Officer at PaxVax since 2007. During his thirty years in industry at major pharmaceutical companies (Boehringer Mannheim, Wyeth-Ayerst) and biotechnology companies (VaxGen, Genelabs, and Sequus), Dr. Gurwith has directed the clinical development of 20 therapeutic drug candidates in the areas of infectious diseases, cardiovascular, cancer, inflammation, and...

Read more
Kurt ReichenVice President, Technical Operations

Mr. Reichen joined PaxVax in July 2014 as VP of Technical Operations. Prior to joining PaxVax, he served as Value Stream Director, Vivotif at Crucell (Johnson & Johnson) for over three years, where he managed the entire manufacturing process with cross-functional responsibilities for Supply Chain, Quality and Engineering. Prior to Crucell, Mr. Reichen worked as Value Stream Director  at...

Read more
Paul Shabram
Paul ShabramVice President, Technical Development

Mr. Shabram joined PaxVax as VP of Operations in July 2007 where he has established a manufacturing facility fully compliant with Good Manufacturing Procedures (cGMP) and oversees the development of all manufacturing processes from initial vaccine vector to finished product. throughout his career he has implemented novel manufacturing processes in both the large pharma (Schering-Plough) and...

Read more
Tom YonkerVice President, Project Management

Mr. Yonker joined PaxVax in 2013 as VP Project Management from KaloBios Pharmaceuticals, where he served as Vice President Project Management.  During his 6 years at KaloBios, Mr. Yonker managed clinical therapeutic monoclonal antibody projects in Asthma, Cystic Fibrosis, and Oncology indications.  During his 30 year career in biopharmaceutics, Mr. Yonker has managed many drug development...

Read more
Jonathan KlockVice President, North America Commercial

Mr. Klock joined PaxVax in 2014 as VP of North America Commercial from Novartis Vaccines, where he was most recently Head of Government Affairs. Prior roles at Novartis include Executive Director of Sales and Director of Public and Private Payor Markets. Mr. Klock has also held sales and government affairs positions at MedImmune and GlaxoSmithKline. In a biotechnology and pharmaceutical industry...

Read more
Jeremy GowlerVice President, International Commercial

Mr. Gowler joined PaxVax in 2014 as VP of International Commercial from Novartis Vaccines, where he was most recently Senior Director of Marketing and Head of the U.S. meningococcal franchise. During his seven years with Novartis Vaccines, Mr. Gowler also served as Director of Medical Affairs and held commercial leadership roles in both the U.S. and Switzerland. Prior to joining the vaccines...

Read more
Lisa DanzigVice President, Clinical Development and Medical Affairs

Dr. Danzig is VP, Clinical Development and Medical Affairs. She joined PaxVax in early 2015 as a Special Advisor for Clinical and Medical Affairs, following 18 years with Novartis Vaccines and Diagnostics, most recently as Global Head of Medical & Scientific Affairs, Diagnostics (acquired by Grifols). Dr. Danzig is an expert in vaccines. She has contributed to the development of meningococcal...

Read more
Martin DeardenVice President, Quality

Mr. Dearden joined PaxVax in 2014 as VP, Quality. He has over 26 years experience in the pharmaceutical industry, with over 20 years focused on the manufacturing of sterile products and biologics. Mr. Dearden started his career at Celltech Biologics and has held roles of increasing responsibility in both small UK based generic companies and also larger global companies such as Aventis and UCB ....

Read more
Kevin SmythVice President, Regulatory Affairs and Pharmacovigilance

Mr. Smyth has served as VP, Regulatory Affairs and Pharmacovigilance since 2014. He has worked extensively with FDA, EMA, PMDA, Health Canada and other regulators during his 20 years of drug development and commercialization experience. Prior to joining PaxVax, Mr. Smyth worked at Baxter for five years as the Global Regulatory Lead for five Biologic drug candidates, including RIXUBIS®,...

Read more
Michelle MaynardVice President Finance

Ms. Maynard joined PaxVax in 2015 as Vice President Finance, Controller where she oversees Global Finance, Information Technology, Tax and Treasury functions. Prior to joining PaxVax, Ms. Maynard was a consultant for Accretive Solutions providing financial support to high tech and biotechnology companies.  Prior to consulting Ms. Maynard held senior finance roles in several public and private...

Read more
Jeff AlexanderVice President of Translational R&D

Dr. Alexander joined PaxVax in 2008 and is currently VP of Translational R&D.  Prior to joining PaxVax, he served on the Research teams of Cytel, Epimmune, and Pharmexa-Epimmune. Dr. Alexander has over 30 years’ experience in the Biotechnology industry in vaccine design and development and extensive knowledge in the use of animal models for evaluating vaccine immunogenicity and efficacy. He...

Read more